ArticleAmerican journal of ophthalmology case reports2022
Dupilumab-associated cicatrizing ocular disease.
Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Dupilumab enables glucocorticoid withdrawal in refractory multisite mucous membrane pemphigoid: a case report.Frontiers in medicine · 2026Article
- Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan.Japanese journal of ophthalmology · 2026Review
- A review on drug-induced dry eye disease.Indian journal of ophthalmology · 2023Review
- Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To describe three cases of bilateral cicatrizing conjunctivitis associated with dupilumab treatment for atopic dermatitis. Observations: Case 1 is a 69 year-old male with a history of mild, stable cicatrizing conjunctivitis thought to be secondary to atopic dermatitis. His cicatrizing disease progressed significantly after starting dupilumab, and then stabilized after dupilumab was discontinued. Case 2 is a 72 year-old male who presented with bilateral cicatrizing conjunctivitis. His symptoms of ocular erythema and irritation started shortly after initiating dupilumab for atopic dermatitis. The dupilumab was discontinued and the patient's symptoms resolved and ocular surface scarring stabilized. Case 3 is a 47 year-old male with a history of allergic conjunctivitis who was found to have new onset unilateral symblepharon approximately 12 months after starting dupilumab for atopic dermatitis. The dupilumab was discontinued and his ocular disease stabilized. However, his cutaneous symptoms worsened significantly, so dupilumab was restarted at half the previous dose. His atopic dermatitis symptoms improved and cicatrizing conjunctivitis remained stable on this regimen. Conclusions and importance: Cicatrizing conjunctivitis with symblepharon formation distinct from ocular cicactricial pemphigoid is a potential side effect of dupilumab therapy for atopic dermatitis. Progression of the cicatrization appears to halt with discontinuation, or potentially dose reduction, of dupilumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.